Giacomo Vignati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giacomo Vignati has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gianpaolo Carrafiello
Interventional Radiology Unit, Department of Radiology, Foundation IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, 20126 Milan, Italy
3 shared publications - Anna Maria Ierardi
Department of Biomedical Sciences and Morphologic and Functional Imaging, Policlinico Universitario G. Martino, University of Messina, 98125 Messina, Italy
2 shared publications - Carolina Lanza
Radiology and Interventional Radiology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy
2 shared publications - Francesco Cicchetti
Postgraduate School in Radiodiagnostics, Università degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy
2 shared publications - Francesco Ugo Iovino
Department of Diagnostic and Interventional Radiology, Foundation IRCCS Cà Granda—Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy
2 shared publications - Gaetano Valerio Davide Amato
Postgraduate School of Radiology, University of Milan, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 20 June 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1573
Real-Life Clinical Use and Outcomes of Fusion Imaging-Guided Percutaneous Microwave Ablation of Hepatocellular Carcinoma: Experience from Two Italian Centers
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Percutaneous thermal ablation is an effective treatment, but standard ultrasound (US) guidance is limited in cases of inconspicuous nodules. Ultrasound fusion imaging (USFI), which overlays cross-sectional imaging onto real-time US is an emerging technique that improves tumor visibility and technical feasibility. This study reports real-life outcomes of USFI-guided microwave ablation (MWA) for HCC in two Italian centers. Materials and Methods: In this multicentric retrospective study, 56 patients with 73 poorly or non-visible HCC nodules underwent USFI-guided percutaneous MWA with no visibility or poor visibility on B-mode US. Technical success, complications, and local tumor control were evaluated, with follow-up imaging at 1 month and every 3 months thereafter. Results: Complete response (CR) at 1 month was observed in 78.1% of nodules, with residual disease (RD) more common in poorly visible nodules than non-visible nodules (18.1% vs. 4.2%, p = 0.019). During a median 13-month follow-up, local tumor progression (LTP) occurred in 9.6% of patients. No significant association was found with difficult tumor location. Conclusions: USFI-guided MWA is a safe and effective option for treating HCC nodules not adequately visualized with conventional US, expanding eligibility to complex cases.
- 20 June 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1573
Open AccessReal-Life Clinical Use and Outcomes of Fusion Imaging-Guided Percutaneous Microwave Ablation of Hepatocellular Carcinoma: Experience from Two Italian Centers
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Percutaneous thermal ablation is an effective treatment, but standard ultrasound (US) guidance is limited in cases of inconspicuous nodules. Ultrasound fusion imaging (USFI), which overlays cross-sectional imaging onto real-time US is an emerging technique that improves tumor visibility and technical feasibility. This study reports real-life outcomes of USFI-guided microwave ablation (MWA) for HCC in two Italian centers. Materials and Methods: In this multicentric retrospective study, 56 patients with 73 poorly or non-visible HCC nodules underwent USFI-guided percutaneous MWA with no visibility or poor visibility on B-mode US. Technical success, complications, and local tumor control were evaluated, with follow-up imaging at 1 month and every 3 months thereafter. Results: Complete response (CR) at 1 month was observed in 78.1% of nodules, with residual disease (RD) more common in poorly visible nodules than non-visible nodules (18.1% vs. 4.2%, p = 0.019). During a median 13-month follow-up, local tumor progression (LTP) occurred in 9.6% of patients. No significant association was found with difficult tumor location. Conclusions: USFI-guided MWA is a safe and effective option for treating HCC nodules not adequately visualized with conventional US, expanding eligibility to complex cases.
- Open Access
- 13 May 2025
- Published by MDPI AG in Preprints.org
Real-Life Clinical Use and Outcomes of Fusion Imaging Guided Percutaneous Microwave Ablation of Hepatocellular Carcinoma: Experience from Two Italian Centres
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Percutaneous thermal ablation is an effective treatment, but standard ultrasound (US) guidance is limited in cases of inconspicuous nodules. Ultrasound fusion imaging (USFI), which overlays cross-sectional imaging onto real-time U is an emerging tech-nique which improves tumor visibility and technical feasibility. This study reports re-al-life outcomes of USFI-guided microwave ablation (MWA) for HCC in two Italian centres. Materials and Methods: In this multicentric retrospective study, 56 patients with 73 poorly or non-visible HCC nodules underwent USFI-guided percutaneous MWA with no visibility or poor visi-bility on B-mode US. Technical success, complications, and local tumor control were evaluated, with follow-up imaging at 1 month and every 3 months thereafter. Results: Complete response (CR) at 1 month was observed in 78.1% of nodules, with residual disease (RD) more common in poorly visible nodules than non-visible nodules (18.1% vs. 4.2%, p=0.019). During a median 13-month follow-up, local tumor progression (LTP) occurred in 9.6% of patients. No significant association was found with difficult tumor location. Conclusion: USFI-guided MWA is a safe and effective option for treating HCC nodules not ade-quately visualized with conventional US, expanding eligibility to complex cases.
- 13 May 2025
- Published by MDPI AG in Preprints.org
Open AccessReal-Life Clinical Use and Outcomes of Fusion Imaging Guided Percutaneous Microwave Ablation of Hepatocellular Carcinoma: Experience from Two Italian Centres
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Percutaneous thermal ablation is an effective treatment, but standard ultrasound (US) guidance is limited in cases of inconspicuous nodules. Ultrasound fusion imaging (USFI), which overlays cross-sectional imaging onto real-time U is an emerging tech-nique which improves tumor visibility and technical feasibility. This study reports re-al-life outcomes of USFI-guided microwave ablation (MWA) for HCC in two Italian centres. Materials and Methods: In this multicentric retrospective study, 56 patients with 73 poorly or non-visible HCC nodules underwent USFI-guided percutaneous MWA with no visibility or poor visi-bility on B-mode US. Technical success, complications, and local tumor control were evaluated, with follow-up imaging at 1 month and every 3 months thereafter. Results: Complete response (CR) at 1 month was observed in 78.1% of nodules, with residual disease (RD) more common in poorly visible nodules than non-visible nodules (18.1% vs. 4.2%, p=0.019). During a median 13-month follow-up, local tumor progression (LTP) occurred in 9.6% of patients. No significant association was found with difficult tumor location. Conclusion: USFI-guided MWA is a safe and effective option for treating HCC nodules not ade-quately visualized with conventional US, expanding eligibility to complex cases.
- Open Access
- 30 October 2024
- Published by MDPI AG in Tomography
- Vol. 10 (11) , 1744-1753
Correlation of Sarcopenia with Coronary Artery Disease Severity and Pericoronary Adipose Tissue Attenuation: A Coronary CT Study
Objective: To investigate the association between sarcopenia, as appraised with CT-derived muscle metrics, and cardiovascular status, as assessed via coronary CT angiography (CCTA) using the Coronary Artery Disease-Reporting and Data System (CAD-RADS) and with pericoronary adipose tissue (pCAT) metrics. Methods: A retrospective observational study conducted on patients who underwent CCTA. The cross-sectional area (CSA) and attenuation values of the paravertebral muscles at the T8 level and the pectoralis major muscles at the T6 level were measured. The patient height was employed for the normalization of the skeletal muscle CSA. The pCAT attenuation around the coronary arteries was assessed, and the CAD severity was graded using the CAD-RADS reporting system. Regression analyses were performed to assess the impact of demographics, clinical factors, and CT variables on the CAD-RADS and pCAT. Results: A total of 220 patients were included (132 males, median age 65 years). Regression analyses showed the associations of CAD with age and sex (p < 0.001). Familiarity with CAD was related to the left anterior descending artery pCAT (p = 0.002) and circumflex artery pCAT (p = 0.018), whereas age was related to the left anterior descending artery pCAT (p = 0.032). Weak positive correlations were found between the lower muscle density and lower pCAT attenuation (ρ = 0.144–0.240, p < 0.039). Conclusions: This study demonstrated weak associations between the sarcopenia indicators and the cardiovascular risk, as assessed by the CAD severity and pCAT inflammation. However, these correlations were not strong predictors of CAD severity, as age and traditional cardiovascular risk factors overshadowed the impact of sarcopenia in the cardiovascular risk assessment.
- 30 October 2024
- Published by MDPI AG in Tomography
- Vol. 10 (11) , 1744-1753
Open AccessCorrelation of Sarcopenia with Coronary Artery Disease Severity and Pericoronary Adipose Tissue Attenuation: A Coronary CT Study
Objective: To investigate the association between sarcopenia, as appraised with CT-derived muscle metrics, and cardiovascular status, as assessed via coronary CT angiography (CCTA) using the Coronary Artery Disease-Reporting and Data System (CAD-RADS) and with pericoronary adipose tissue (pCAT) metrics. Methods: A retrospective observational study conducted on patients who underwent CCTA. The cross-sectional area (CSA) and attenuation values of the paravertebral muscles at the T8 level and the pectoralis major muscles at the T6 level were measured. The patient height was employed for the normalization of the skeletal muscle CSA. The pCAT attenuation around the coronary arteries was assessed, and the CAD severity was graded using the CAD-RADS reporting system. Regression analyses were performed to assess the impact of demographics, clinical factors, and CT variables on the CAD-RADS and pCAT. Results: A total of 220 patients were included (132 males, median age 65 years). Regression analyses showed the associations of CAD with age and sex (p < 0.001). Familiarity with CAD was related to the left anterior descending artery pCAT (p = 0.002) and circumflex artery pCAT (p = 0.018), whereas age was related to the left anterior descending artery pCAT (p = 0.032). Weak positive correlations were found between the lower muscle density and lower pCAT attenuation (ρ = 0.144–0.240, p < 0.039). Conclusions: This study demonstrated weak associations between the sarcopenia indicators and the cardiovascular risk, as assessed by the CAD severity and pCAT inflammation. However, these correlations were not strong predictors of CAD severity, as age and traditional cardiovascular risk factors overshadowed the impact of sarcopenia in the cardiovascular risk assessment.
- Top Cited PapersOpen Access
- 12 July 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (14) , 1506
AI in Radiology: Navigating Medical Responsibility
The application of Artificial Intelligence (AI) facilitates medical activities by automating routine tasks for healthcare professionals. AI augments but does not replace human decision-making, thus complicating the process of addressing legal responsibility. This study investigates the legal challenges associated with the medical use of AI in radiology, analyzing relevant case law and literature, with a specific focus on professional liability attribution. In the case of an error, the primary responsibility remains with the physician, with possible shared liability with developers according to the framework of medical device liability. If there is disagreement with the AI’s findings, the physician must not only pursue but also justify their choices according to prevailing professional standards. Regulations must balance the autonomy of AI systems with the need for responsible clinical practice. Effective use of AI-generated evaluations requires knowledge of data dynamics and metrics like sensitivity and specificity, even without a clear understanding of the underlying algorithms: the opacity (referred to as the “black box phenomenon”) of certain systems raises concerns about the interpretation and actual usability of results for both physicians and patients. AI is redefining healthcare, underscoring the imperative for robust liability frameworks, meticulous updates of systems, and transparent patient communication regarding AI involvement.
- 12 July 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (14) , 1506
Top Cited PapersOpen AccessAI in Radiology: Navigating Medical Responsibility
The application of Artificial Intelligence (AI) facilitates medical activities by automating routine tasks for healthcare professionals. AI augments but does not replace human decision-making, thus complicating the process of addressing legal responsibility. This study investigates the legal challenges associated with the medical use of AI in radiology, analyzing relevant case law and literature, with a specific focus on professional liability attribution. In the case of an error, the primary responsibility remains with the physician, with possible shared liability with developers according to the framework of medical device liability. If there is disagreement with the AI’s findings, the physician must not only pursue but also justify their choices according to prevailing professional standards. Regulations must balance the autonomy of AI systems with the need for responsible clinical practice. Effective use of AI-generated evaluations requires knowledge of data dynamics and metrics like sensitivity and specificity, even without a clear understanding of the underlying algorithms: the opacity (referred to as the “black box phenomenon”) of certain systems raises concerns about the interpretation and actual usability of results for both physicians and patients. AI is redefining healthcare, underscoring the imperative for robust liability frameworks, meticulous updates of systems, and transparent patient communication regarding AI involvement.